ALEXION PHARMACEUTICALS, INC.

(ALXN)
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada

01/25/2022 | 07:09am EDT

In December 2021, the Patented Medicine Prices Review Board (the "PMPRB") and the Minister of Health issued two updates regarding the Regulations Amending the Patented Medicines Regulations (the "Amendments") and the new PMPRB Guidelines (the "New Guidelines"). These notably include a further deferral of the coming-into-force date of the Amendments. The updates, along with the Federal Court of Appeal's ("FCA") July 2021 decision in Alexion Pharmaceuticals Inc v Canada (Attorney General), 2021 FCA 157 ("Alexion"), may have important implications for pharmaceutical patentees in Canada as they implement or revise their pricing strategy for 2022 and beyond.

December 2021 Updates

First, on December 17, 2021, the PMPRB announced that it had decided not to proceed with three amendments to the New Guidelines proposed in July 2021. The three proposed amendments were a change in the definition of "Gap medicines" to reflect the then-current coming-into-force date of the Amendments (January 1, 2022), replacing references to the "PMPRB11" comparator countries with the term "Schedule Countries", and the international price tests for Grandfathered medicines and their line extensions. These proposed amendments were subject to a consultation period between July 15 and August 31, 2021, and the stakeholder submissions are now available online.

Second, on December 23, 2021, the Minister of Health announced that the coming-into-force of the Amendments would be further deferred, from January 1, 2022 to July 1, 2022. The New Guidelines, which operationalize the amendments, are expected to come into effect on the same date as the Amendments.

Given the decision not to amend the definition of Gap medicines to include medicines for which a DIN was assigned on or after August 21, 2019 and prior to January 1, 2022 and first sold in Canada prior to January 1, 2022 (and barring future amendment to the definition to reflect the new coming-into-force date), a medicine first sold in Canada on or after July 1, 2021 would be considered a New Medicine under the New Guidelines. Under the New Guidelines, the applicable price test for New Medicines is a maximum list price ("MLP") set at the median international price ("MIP"). Nevertheless, at present and until the Amendments come into force, these medicines are still subject to the Compendium of Policies, Guidelines and Procedures or the "Old Guidelines". Under the Old Guidelines, the applicable price test for any medication depends on the level of therapeutic improvement (i.e. whether it is a breakthrough drug, has substantial, moderate or slight to no improvement) and can involve therapeutic class comparisons and/or international price comparisons.

Thus, although patentees might have expected and even waited to launch their medications as "New Medicines" to be subject to a MIP test, patentees are asked to grapple with the Old Guidelines to ensure compliance and avoid an investigation by the PMPRB. If the MLP of their medicine then changes under the New Guidelines, upon the coming-into-force of the Amendments, patentees may be forced to change their price.

This ever-changing pricing landscape and unpredictability may make price setting strategy and negotiations with payers challenging.

In this context, recent case law may be enlightening.

The Alexion Decision

In particular, in Alexion, the FCA defined the PMPRB's mandate as "preventing abusive pricing, i.e., excessive pricing made possible by the abuse of the monopoly power given by a patent" (para 11).  This proper purpose is contrasted with the improper purpose of price control and ensuring "reasonable pricing" (see paras 27, 49-51). General price control is not a part of the balance struck by the provisions of the Patent Act which represents a balance between incentivizing innovation and protecting against abuse of the statutory monopoly (see paras 40, 50, 56). An application by the Attorney General for leave to appeal the decision to the Supreme Court of Canada is currently pending. A Fasken litigation team represented Alexion Pharmaceuticals Inc. in this matter before both the Federal Court and Federal Court of Appeal.

See also how the Superior Court of Quebec's decision regarding the constitutionality of the PMPRB may further support this line of reasoning.

Whether the articulation of the PMPRB's mandate in these cases can provide support to patentees in the context of an excessive price investigation or hearing, including for Grandfathered or Gap medicines, or for New Medicines caught between the old and new regimes, remains to be seen.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Dara Jospé
Fasken
The Stock Exchange Tower,PO Box 242
Suite 3700
800 Victoria Square
Montreal
Ontario
QC H4Z 1E9
CANADA
Tel: 4163668381
Fax: 4163647813
E-mail: sdookhoo@fasken.com
URL: www.fasken.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about ALEXION PHARMACEUTICALS, INC.
05/05Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy..
AQ
04/28Ultomiris approved in the US for adults with generalised myasthenia gravis
AQ
04/26BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry
AQ
04/11PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing
AQ
03/31SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)
AQ
03/29PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat..
AQ
03/18Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
03/17AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir..
AQ
03/01AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t..
AQ
03/01Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializin..
CI
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ALEXION PHARMACEUTICALS, INC.0.00%40 336
CSL LIMITED-3.62%93 394
SAMSUNG BIOLOGICS CO.,LTD.-13.07%43 585
BIOGEN INC.-17.01%29 160
WUXI BIOLOGICS (CAYMAN) INC.-43.92%27 891
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-20.75%23 276